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W Zalt~a,/LJ, Mos~ J, ~ - . .  PJ, Schw~m~ GM~ Vincent. 
S,G, P¢.~;, J, ~ F~H, I.oolti. J A- ~ M,T, K¢4~9, 
ke, uwn ~ LOT1, LOT'S_ LQ!~ ae4 J~m,~k~ L a n ~  (JLNS) 
~ eemUed ~n u~e ~m~a~aJ LOTS ne0m~. 
~ In 3~ I~ ~ Of LOTS ~ 533 f~m~ ~ ~ 
tosted I~  LOT1. LQT~ amd LOT3 ~ ~ ~ ~ l~em ~ to LQT1 (n 
= 111). LOT2 (n = ~1). ~ LQT3 (n = 62), ~ tha ~ ol g,,.~,~=~l 
¢~s .~m JUgS m ~ 53 ~ I~s w~ co.-,.~-.la~ dealnese 
were We~mm to ~ ~ ~r  KVt.OTt. 
= 63%. LQT2 = 47%, LOT3 = II~Y~. and JUgS =; 79%. Caxdiac eve~nt free 
sundval from tWl~ foc eadt genolype am sbewn hefow (p <0.001): 
,, ._  
: :  . . . . . .  
C~nc~s~,~ S~:~c gene kd~ge us as~c~ed w~ d~rem kx~g-~n'~ 
outo(~ne o~ LQTS patients wdh h~jt~est i~robabdW Of can~ac events aasocP 
ated wflh KVLQT1 mutations, to, owed by HERG n~latmns, end lowest with 
SCN,SA gene ~ 
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ProthmmboUc GeneUc Risk Factors in Young 
Sundvom of Myocanllal hlfamUon 
PJL Idedi~. O. ~ .  R. Feh~mau. M Tubam. M. GaNam. F. O~am. 
E Saoc~, F D.ca. P M Mannuec~. Ospeda~ Nkjua.-0~ lano: Pot~ct/n¢o 
San lt~tteo, Pev~ Os~-GaA~ San Cami~k~ Rom~ O~edale G.B. AP~.gagni, 
Fon~: A. B~h~ Bonorm Hemo~a and Thn~nlx~s Cen~, M~o.  IMly 
I r ~  thrombotic fan~y increases the risk of acute myocardial in- 
farction, especially in young adults. Genetic prothrembol¢ fectom that may 
inftuence the risk Of myocardial infarction have recently been ~ To in- 
vestigate the association between the risk of myocan:lial infarcto~ at a young 
age and five genetic factors predfspo~ng to thromhoc~. (i.e. 4G/5G poly- 
moq)hism in the PAl-1 gene promoter. PLA1/PLA2 polymoq)hism of platelet 
glycoprutein Ilia, the C6771 mutation in the metbylane-tetrahydmfolate m- 
ducfase gene, the G1691A mutation in the factor V gene and the G20~10A 
mutation in the pmthrembin gene), we camed out a case-control study of 
200 sun/ivors of myocardial infarctions who had experienced the event be- 
fore the age of 45 years and 200 age and sex- matched control subjects. 
The presence of the PLA1/PLA2 polymorphism was found to be the only 
genetic factor associated with the risk of developing myocardial infarction at 
a young age. (OR = 1.67; 95"/0 CI 1.08 to 2.59). The risk associated with 
smoking (OR 6.6; 95% CI 4-11), hypertension (OR 13.9; 95°/,, CI 5.7-13.9) 
and diabetes (OR 3.6; 95% CI 1.3-10.3) was at least doubled in the presence 
of the PLA2 allele (smoking: OR 13.1, 95% CI 5.9-30; hypertension: OR: 
29.5, 95% CI 4-789; diabetes: OR 10.1,95°,;, CI 1.26-27.3). The presence of 
the G1691A mutation in the factor V gene was associated with an increased 
risk of myocardial inlamtion only in smokers (OR 15.95% CI 2.7-113). There 
was no evidence of any association between the other four genetic factors 
alone, or of an additive effect of the combination of two or more genetic fac- 
tors, and the risk of premature myocardial infarction. In conclusion, bearing 
me PLAImt-A~ polymom~m was ~ onty 0or~ ~=to~ a~s~at~l w~ 
t)~ ~ of ~ - , ~  myoca~Pal tnfa¢t~on at a young ago, 11~ 01601A 
mul~im m I~e~ facto~ v 9tm~ wm ~ w~ m ~ ~sk orW m 
mnueeo~l W I~ Pmlee¢~ M olt~f ememememal esk ~*lmz. 
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~ Iq~i lh l l  Mf lM Rl~,Ml~on Is • C ienet~l ly  
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~ rx. us4 
AI,ai N:m~a~:~ (AF), e~e most con~Qn suslamed ~ a~cls ove~ 2 
nvlb~ ~ a,~l ~¢cou~s f0~ one mm~ Of ag ~ p~. me age Of 
~ y~m~, Un~l mc~ areal ~ was not mgamd as hav~ a ~1~ 
et~'c~. In reST, we ~ abm~y w~ AF a~ malX~ ~e r~ ~ 
~ S ~ , n ~  ~ (~pnsmg a t~al Of lZ2 ~ 
~ ~ ~m~ a~'~m w~ k=, ~ 5 am gemm~ ~ to 10q~4 (LOO >10) 
t.3 cM. ~ ~e tot ~ Of k': was le yem rang~ 
from I m0~m to 82 ym. Mo~ Of ~ ~ v~,m AF m ~ 
pmlk:ula~ those befow the a0e Of 40. It is Of imemst I*~ famU~ AF m 
me ~g aF;~a~ to ha~ a masmab~ ~ wm~:u~ me a~ 
~.~ fmrn pa~lX~S~m~s seems to be wen to;,~,_.~:_..~.~_ we hav~ m ~ 
ped~,med ~ 2 Of me ne~ fam~es ~ 5 0N~ mad.~s tRm/*~rmd to 
me 10q24 m~n. Ga=~c ~mt~le Of me ~ to I0¢124 ts  e~=~l  mm 
a LOD scorn Of <-2.  ~ e~ludad ~ to t~e I0q24 locuS, studies 
am .~w u.dem~ to ¢~ly  ~ .ew kx~ 350 l~gNy ,~mat~e ma~e~, 
(~ete,:tal~e by PCR, hove been selected to ~,~-~ the homan 0e~eme wm~ 
the damnce betwem any 2 madam not to e~¢eed 10 cM. Eve~ anempt 
m being made to exmnd umg lamTam and iden~/new lan~T~es. Thus. 
dasipite lack Of am~m~ss tha~ ~ AF is an mtm~ed lsease, om recent 
~ mu, base mdica~es the pmvakmce is I~gher n~m expectsd. It 
is l~Ny rdmly real "kme I~rs"  and eady o,-~e; AF an hava a gene~c 
bass. E.~dusion of linkage in these fan~l~ to 10(124 inortcates at least 2 
,~-~ are ~ fo~ AF a~l most likoly there are meny more, 
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Vadabie Phenotype of Long QT Syndrome Patients 
W~ me Same Gene~ Defect 
S.G. Prio~L C. Nal:Or~mo, PJ, S¢~waMz, R. Mad~ D. McDonalds II, 
I. DenF~, P. Gb;,;~-,c-y, J.A. To~om, V. Paganini. G. Casan. Mo/ecu/ar 
~ ~ Mauge~ Pare. na/y 
it hos been shown that the dincal i~motype Of the Long QT ~ 
(LQTS) may vmy amo~ mose ¢~s camy~ d, fferent mutmmns on me s=~e 
~#,-,~. Since a mutmional hot spot has been ~;* ,~ at Ihe ~ 246 m 
the KVLOTf 0,~,-,,~ (the gene ~;ed  to LOT1), it becomes intmuling to 
assese if pa~,e~s w~ mutations at me seine site r, rwent con~non pheon~X 
charactedst¢s. We hava therefore estabt~h,~i a woddwfde data base to 
co~ect families wrih m ~  at this site using Intemat for centacls and 
data exchange. So far we collected clinical data On 25 (14 f~nalas) affect~ 
imlividuals in 5 fam~liss from Italy. France, United States and , ;a~.  When 
clinical features were compared a large h~;,,~o,;,~-,~;;y was observed: OTc 
vaned batween 460 and 630 msec, the numb~ of synco~oal egtsodas hefore 
therapy varied from none (11 asymptomatlc germ car~; ; )  to >10. age at 
first syrcope ranged from 4 to 31 yearn and age at suddcm death (4~25) frem 
14 tO 35 years. ~ fact that 44% of (:jefle cante~ remained 8Sy,,~,,.m,o,~ 
suo0~t that penetrence of the disease in (:amen; of the disease is fairly 
low. White the A246 data base is continuing onrellment as new patients are 
genotyped, prelrminary data point o the evidence that even in the suL~gro,Jp el 
ptS with the same mutation the ciin~l presentation is not uniform. Therefore 
caution is required when extrapolating prognostic implications based oft the 
molecular defect. Present data also su00est that the genetic defect is the 
substrate of the disease bet that its clinical phenotype is pmfounoly affected 
by yet unknown factors (en~ronment. modifiers genes). 
